Stock listing
Kringle Pharma, Inc.
Selected listing: 4884 · TSE · JPY · JP
Kringle Pharma, Inc. (Tokyo:4884), Health Technology. Latest release Sep 24, 2026: Kringle Pharma Announces IND Submission to the U.S. FDA for Oremepermin…
- Ticker
- Tokyo:4884
- Asset type
- Stock
- Sector
- Health Technology
- Industry
- Biotechnology
- Exchange
- Tokyo
- Currency
- JPY
About Kringle Pharma, Inc.
Kringle Pharma, Inc. is a public company traded under the ticker 4884 on the Japanese market. Kringle Pharma aims to address unmet medical needs through its research and development efforts.
Latest news from Kringle Pharma, Inc.
Kringle Pharma Announces IND Submission to the U.S. FDA for Oremepermin Alfa for the Treatment of Acute Spinal Cord Injury
September 23, 2026
Financial Results for the Nine Months Ended June 30, 2026 [Japanese GAAP] (Non-consolidated)
August 10, 2026
Kringle Pharma Advances the Registrational Program for Oremepermin Alfa in Japan with Initiation of Additional Phase 3 in Acute Spinal Cord Injury
July 23, 2026
Kringle Pharma : Update on the Investigator-initiated Phase 2 Study in Patients with ALS
August 12, 2022
Kringle Pharma : Files Patent Application for Treatment of Chronic Spinal Cord Injury
March 11, 2022
Research Kringle Pharma, Inc.
Kringle Pharma, Inc. company profile
View the public company page for Kringle Pharma, Inc. on 6ix.
Kringle Pharma, Inc. news
Read company news and market updates connected to Kringle Pharma, Inc..
Kringle Pharma, Inc. investor events
Find investor webinars, events, and replay context for Kringle Pharma, Inc..